Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Oligonucleotide Pool Market

ID: MRFR/HC/55083-HCR
200 Pages
Satyendra Maurya
Last Updated: February 06, 2026

South America Oligonucleotide Pool Market Research Report By Type (DNA, RNA), By Application (Research, Diagnostic & Therapeutics, Others), By End User (Commercial Research, Pure Academic Research, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Oligonucleotide Pool Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Million)
  49.     4.1.1 Gene Synthesis
  50.     4.1.2 Gene Editing
  51.     4.1.3 PCR Amplification
  52.     4.1.4 Next Generation Sequencing
  53.     4.1.5 Antisense Oligonucleotides
  54.   4.2 Healthcare, BY End Use (USD Million)
  55.     4.2.1 Academic Research
  56.     4.2.2 Pharmaceutical Companies
  57.     4.2.3 Biotechnology Firms
  58.     4.2.4 Diagnostic Laboratories
  59.   4.3 Healthcare, BY Type (USD Million)
  60.     4.3.1 Custom Oligonucleotides
  61.     4.3.2 Pre-Designed Oligonucleotides
  62.     4.3.3 Universal Oligonucleotides
  63.   4.4 Healthcare, BY Technology (USD Million)
  64.     4.4.1 Solid Phase Synthesis
  65.     4.4.2 Liquid Phase Synthesis
  66.     4.4.3 Microarray Technology
  67.   4.5 Healthcare, BY Distribution Channel (USD Million)
  68.     4.5.1 Online Sales
  69.     4.5.2 Direct Sales
  70.     4.5.3 Distributors
  71. 5 SECTION V: COMPETITIVE ANALYSIS
  72.   5.1 Competitive Landscape
  73.     5.1.1 Overview
  74.     5.1.2 Competitive Analysis
  75.     5.1.3 Market share Analysis
  76.     5.1.4 Major Growth Strategy in the Healthcare
  77.     5.1.5 Competitive Benchmarking
  78.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  79.     5.1.7 Key developments and growth strategies
  80.       5.1.7.1 New Product Launch/Service Deployment
  81.       5.1.7.2 Merger & Acquisitions
  82.       5.1.7.3 Joint Ventures
  83.     5.1.8 Major Players Financial Matrix
  84.       5.1.8.1 Sales and Operating Income
  85.       5.1.8.2 Major Players R&D Expenditure. 2023
  86.   5.2 Company Profiles
  87.     5.2.1 Thermo Fisher Scientific (US)
  88.       5.2.1.1 Financial Overview
  89.       5.2.1.2 Products Offered
  90.       5.2.1.3 Key Developments
  91.       5.2.1.4 SWOT Analysis
  92.       5.2.1.5 Key Strategies
  93.     5.2.2 Integrated DNA Technologies (US)
  94.       5.2.2.1 Financial Overview
  95.       5.2.2.2 Products Offered
  96.       5.2.2.3 Key Developments
  97.       5.2.2.4 SWOT Analysis
  98.       5.2.2.5 Key Strategies
  99.     5.2.3 Eurofins Genomics (DE)
  100.       5.2.3.1 Financial Overview
  101.       5.2.3.2 Products Offered
  102.       5.2.3.3 Key Developments
  103.       5.2.3.4 SWOT Analysis
  104.       5.2.3.5 Key Strategies
  105.     5.2.4 Bioneer Corporation (KR)
  106.       5.2.4.1 Financial Overview
  107.       5.2.4.2 Products Offered
  108.       5.2.4.3 Key Developments
  109.       5.2.4.4 SWOT Analysis
  110.       5.2.4.5 Key Strategies
  111.     5.2.5 GenScript (CN)
  112.       5.2.5.1 Financial Overview
  113.       5.2.5.2 Products Offered
  114.       5.2.5.3 Key Developments
  115.       5.2.5.4 SWOT Analysis
  116.       5.2.5.5 Key Strategies
  117.     5.2.6 Sigma-Aldrich (US)
  118.       5.2.6.1 Financial Overview
  119.       5.2.6.2 Products Offered
  120.       5.2.6.3 Key Developments
  121.       5.2.6.4 SWOT Analysis
  122.       5.2.6.5 Key Strategies
  123.     5.2.7 Bio-Rad Laboratories (US)
  124.       5.2.7.1 Financial Overview
  125.       5.2.7.2 Products Offered
  126.       5.2.7.3 Key Developments
  127.       5.2.7.4 SWOT Analysis
  128.       5.2.7.5 Key Strategies
  129.     5.2.8 Agilent Technologies (US)
  130.       5.2.8.1 Financial Overview
  131.       5.2.8.2 Products Offered
  132.       5.2.8.3 Key Developments
  133.       5.2.8.4 SWOT Analysis
  134.       5.2.8.5 Key Strategies
  135.   5.3 Appendix
  136.     5.3.1 References
  137.     5.3.2 Related Reports
  138. 6 LIST OF FIGURES
  139.   6.1 MARKET SYNOPSIS
  140.   6.2 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  141.   6.3 SOUTH AMERICA MARKET ANALYSIS BY END USE
  142.   6.4 SOUTH AMERICA MARKET ANALYSIS BY TYPE
  143.   6.5 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
  144.   6.6 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  145.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  146.   6.8 RESEARCH PROCESS OF MRFR
  147.   6.9 DRO ANALYSIS OF HEALTHCARE
  148.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  149.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  150.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  151.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  152.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
  153.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  154.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
  155.   6.17 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  156.   6.18 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
  157.   6.19 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  158.   6.20 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
  159.   6.21 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  160.   6.22 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  161.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  162. 7 LIST OF TABLES
  163.   7.1 LIST OF ASSUMPTIONS
  164.     7.1.1
  165.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  166.     7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  167.     7.2.2 BY END USE, 2026-2035 (USD Million)
  168.     7.2.3 BY TYPE, 2026-2035 (USD Million)
  169.     7.2.4 BY TECHNOLOGY, 2026-2035 (USD Million)
  170.     7.2.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
  171.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  172.     7.3.1
  173.   7.4 ACQUISITION/PARTNERSHIP
  174.     7.4.1

South America Healthcare Market Segmentation

Healthcare By Application (USD Million, 2022-2035)

  • Gene Synthesis
  • Gene Editing
  • PCR Amplification
  • Next Generation Sequencing
  • Antisense Oligonucleotides

Healthcare By End Use (USD Million, 2022-2035)

  • Academic Research
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Diagnostic Laboratories

Healthcare By Type (USD Million, 2022-2035)

  • Custom Oligonucleotides
  • Pre-Designed Oligonucleotides
  • Universal Oligonucleotides

Healthcare By Technology (USD Million, 2022-2035)

  • Solid Phase Synthesis
  • Liquid Phase Synthesis
  • Microarray Technology

Healthcare By Distribution Channel (USD Million, 2022-2035)

  • Online Sales
  • Direct Sales
  • Distributors

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓